INVESTIGATION: A six-year-old's death, hidden for sixteen months in a gene-editing scandal

A six-year-old girl died in March 2025, seven days after an experimental gene-editing therapy, and the world did not learn of it until July 23, 2026. The journal Science and the watchdog site Retraction Watch revealed that day that the child, referred to as "Mei," had undergone a base editing procedure at the affiliated Xinhua Hospital, part of the Shanghai Jiao Tong University School of Medicine. Sixteen months separate her death from its public disclosure. Sixteen months of silence is not an administrative delay. It is a decision, renewed every single day it went unreviewed.

The procedure aimed to correct, in Mei, a rare genetic mutation behind a serious disease, using a technique derived from CRISPR-Cas9 that chemically edits a single DNA base without cutting both strands. The trial's lead investigator, Professor Zilong Qiu, had nonetheless published in February 2026 in the journal Nature a paper claiming that this same therapy effectively corrected the mutation in human cells and in the brains of mice and monkeys. It mentioned neither Mei's death nor the serious side effects observed in the primates tested before the clinical trial.

This investigation draws on the journalistic revelations of Science and Retraction Watch, on documents supplied by Mei's family, and on the Asian and Western press coverage that has followed the story since July 23. It separates what is documented through concrete records — payments, publications, mortality reports — from what remains part of an ongoing inquiry, opened by the university itself on July 26, 2026. The subject touches the trust the public can place in cutting-edge genetic research, and that trust is not rebuilt with approximations.

What Science and Retraction Watch revealed on July 23

A death that came seven days after the injection

According to information relayed by Chosun Biz, citing Science, and by The Epoch Times, Mei died in March 2025, seven days after receiving the experimental injection at Xinhua Hospital. The hospital's mortality review committee concluded that the viruses used to carry the gene therapy to its target had triggered a fatal immune response. A child died of the very reaction the trial was supposed to prevent. A therapy meant to repair a gene triggered the reaction that killed the child it was supposed to save.

Science reports that the hospital allegedly failed to verify the safety data from prior primate experiments before authorizing the move to a human clinical trial. This omission, if confirmed, is not a minor bureaucratic lapse: it strikes at the core of the protocol meant to protect a patient before any experimental intervention on their body. The internal report existed. Nobody escalated it in time.

Sixteen months between the death and its disclosure

Between Mei's death in March 2025 and its public revelation on July 23, 2026, more than a year passed without the hospital, the university, or the researcher in charge disclosing the information on their own initiative. It was the effort of Mei's parents, who supplied documents to Science, that pulled the case out of the shadows. Without that effort, nothing suggests the public would ever have learned what happened at Xinhua Hospital.

This delay takes on particular weight in light of another fact documented by the South China Morning Post: the hospital had already paid, in September 2025, a fine of roughly 24,000 yuan, close to 3,500 US dollars, to local health authorities, without any public sanction being applied to Professor Qiu at the time. The institution therefore knew, six months after the death, that a problem existed — and said nothing to the outside world.

The Nature publication, or the omission that becomes a conflict of interest

A paper published without mentioning the death or the side effects

In February 2026, nearly a year after Mei's death, Professor Zilong Qiu published in Nature the results of his base editing therapy, presented as effective at correcting the targeted mutation in human cells and in the brains of mice and monkeys. The paper made no mention of the girl's death nor of the severe organ damage observed in four monkeys that had received the same therapy before the human clinical trial. A researcher published a success while concealing a fatal failure. A researcher who publishes a success and hides the death that accompanied it is no longer reporting science; he is curating it.

Mei's parents supplied Science with documents showing precisely this organ damage in the four tested primates. This evidence, if confirmed by the university inquiry, would establish that the warning signs existed even before the move to a clinical trial on a child, and that they were neither published nor factored into the decision to proceed. A top-tier journal deemed the paper publishable without that information.

A conflict of interest that strikes at the heart of scientific integrity

Professor Qiu occupies here a dual position that raises a direct integrity problem: he is both the investigator responsible for the clinical trial that led to Mei's death, and the author of the scientific publication that omitted mention of that death as well as the side effects observed in animals. A researcher who evaluates his own therapy and decides what to disclose about it is no longer a neutral scientist; he becomes judge and party.

This configuration is not a technical detail: it means the international scientific community, reading the Nature article in February 2026, had no way of knowing that a child had died following the therapy described as a success. The clinical trial itself, Science notes, was never published in a medical journal after the death — a lack of transparency that compounds the omission in the Nature paper.

The $860,000 paid as "development fees"

A payment that contradicts the claimed non-commercial nature of the trial

Documents supplied by Mei's family to Science describe a payment of roughly 860,000 US dollars, close to 1.2 billion South Korean won according to the conversion reported by Chosun Biz, paid as "development fees" for the therapy administered to Mei. That figure directly calls into question the supposedly non-commercial nature of the clinical trial the child took part in. A trial described as free generated nearly a million dollars in fees.

None of the sources reviewed specify who received this payment or how it was divided among the parties involved in developing the therapy. This financial gray zone is among the elements the university's inquiry will need to clarify, since it bears directly on whether commercial interests may have influenced the decision to proceed with the trial despite the warning signs in the primates.

What Qiu's silence leaves unanswered

The South China Morning Post reported, on July 26, 2026, a statement attributed to Professor Qiu: "All answers will be provided by the medical school leadership." That statement passes the burden of transparency to the institution rather than to the researcher directly implicated. The principal person named stays silent and defers to others.

No source consulted for this investigation reports a detailed response from Qiu on the reasons for the omission in Nature, on the 860,000-dollar payment, or on the failure to verify animal safety data before the clinical trial. This absence of a direct response is, in itself, a fact to report rather than a gap to fill with assumption.

The university inquiry opened on July 26

A late but real institutional reaction

The Shanghai Jiao Tong University School of Medicine announced the opening of an inquiry after the revelations from Science and Retraction Watch. The announcement came three days after the July 23 publication, and more than sixteen months after Mei's death. The university moves only when the press forces it to move.

No source consulted specifies the timeline of this inquiry, its exact scope, or whether it will include an independent review of the animal data that predated the clinical trial. This lack of methodological detail limits, at this stage, the ability to assess whether the inquiry will produce verifiable answers or amount to institutional communication designed to calm public controversy.

What the hospital's mortality committee had already established

The mortality review committee at Xinhua Hospital had, even before the public revelations, concluded that the viral vectors used to deliver the gene therapy had triggered the immune response that caused Mei's death. That internal conclusion therefore existed well before the public disclosure of July 2026, which reinforces the hypothesis of institutional knowledge of the problem for over a year without external communication.

The fact that this conclusion comes from the hospital's own committee, not from an independent external body, calls for caution about its exact weight: it establishes a probable medical cause, but says nothing, at this stage, about the precise responsibilities in the conduct of the trial or in the decision not to disclose the incident earlier to outside bodies.

Base editing, a promise now under scrutiny

A technique presented as more precise than classic CRISPR-Cas9

Base editing is a technique derived from CRISPR-Cas9, but unlike the original method, it does not cut both DNA strands. It chemically edits a single genetic base at a time, generally presented by the scientific community as a more precise and potentially safer approach for correcting the point mutations behind rare diseases. The promise of precision did not prevent Mei's death.

This reputation for greater precision makes Mei's death all the more significant for the field: it is not a failure attributable to a technique considered risky from the outset, but an incident that occurred with a method the scientific community had, until this revelation, regarded as one of the most promising advances in modern gene therapy for rare genetic diseases.

What the primate trials failed to stop

The four monkeys that showed severe organ damage even before the move to the clinical trial on Mei represented, in theory, the exact signal a safety protocol is designed to detect and act on before authorizing an intervention on a human being. The fact that the trial proceeded on a child anyway raises directly the question of whether Xinhua Hospital's ethical approval procedures were fully respected. Four monkeys showed what was coming. The trial went ahead anyway.

No source consulted allows a definitive statement, at this stage, that Xinhua Hospital's ethics committees were informed of this organ damage before giving their approval for the clinical trial on Mei. This question figures precisely among those the university inquiry opened on July 26 will need to settle, with potential consequences for the validity of the initial approval itself.

What Mei's family made public

Documents that contradict the official version

The effort by Mei's parents in approaching Science is the starting point of this entire affair. Without their documents — evidence of the harm to the primates and of the 860,000-dollar payment — the incident would have remained confined to an internal mortality report, never brought to the attention of the public or the international scientific community. A grieving family did the work the institution refused to do.

This dynamic is not unique to this case: in several documented scientific scandals around the world, it has been victims' relatives, rather than institutional oversight mechanisms, who brought problematic practices to light. That underlines a structural fragility in internal monitoring systems whenever no independent outside pressure is applied to a medical research institution.

What the silence of Chinese institutions reveals

Neither Xinhua Hospital, nor Shanghai Jiao Tong University, nor Professor Qiu, according to the available sources, took the initiative to make Mei's death public before Science and Retraction Watch did so. This lack of initiative, sustained for sixteen months, is the heaviest fact in this case, heavier even than the precise medical cause of death.

It would nonetheless be excessive to claim, on the available evidence alone, that a coordinated cover-up strategy involving all these actors acting in concert existed. What the facts establish is a succession of individual and institutional silences whose cumulative effect was to considerably delay the public disclosure of this affair.

The repercussions for global genetic research

Trust to be rebuilt across the entire field of base editing

This scandal comes at a moment when base editing is drawing growing interest from laboratories around the world as a safer alternative to classic gene editing. The revelation of a death concealed for more than a year, combined with an incomplete scientific publication in a journal as prestigious as Nature, risks undermining public trust in the entire field, far beyond the specific case of Xinhua Hospital and its direct officials.

This erosion of trust does not concern public opinion alone: it also touches the way scientific journals review submitted papers, and the rigor with which they check for conflicts of interest or missing data among authors. A journal that publishes a success without knowing the failure that came with it has not really verified what it is publishing.

The role of Retraction Watch and outside vigilance

Retraction Watch, a watchdog site specializing in tracking retractions and scientific fraud, played a central role in uncovering this affair alongside Science. This kind of independent organization is, in numerous recent scientific scandals around the world, one of the only mechanisms genuinely capable of documenting and publicizing practices that the institutions involved would prefer to keep internal and out of the media spotlight.

No information available indicates whether Nature is considering retracting or correcting the paper Qiu published in February 2026 in light of these revelations. That question now falls within the editorial responsibility of the journal, separate from the university inquiry opened by Shanghai Jiao Tong and its forthcoming conclusions.

The questions the university inquiry will need to settle

The exact timeline of internal decisions

The inquiry opened on July 26, 2026 will need to establish a precise timeline of internal decisions made at Xinhua Hospital between the first troubling results in the primates and Mei's death, and then between that death and the publication of the paper in Nature in February 2026. Every step of this timeline will determine who knew what, and at exactly which point in the sequence.

It will also need to establish whether the hospital's ethics committee was fully informed of the harm observed in the monkeys before authorizing the trial on a child, and whether the 24,000-yuan fine paid in September 2025 amounted to an implicit acknowledgment of a failure already identified internally by the institution itself.

The question of the $860,000 payment

The inquiry will also need to clarify the exact nature of the 860,000-dollar payment described as "development fees," its recipient, and its relationship to the claimed non-commercial nature of the trial. This financial clarification could prove decisive in establishing whether economic considerations weighed on the decision to proceed with the trial despite the warning signs observed in the primates tested beforehand.

Without this clarification, the question of whether the money preceded or followed the scientific decisions will remain open, and will continue to fuel suspicion of a trade-off between patient safety and the financial interests of the research project led by Qiu's team.

A case that fits within a broader debate on research in China

Precedents that weigh on the sector's credibility

This scandal cannot be read in isolation from the recurring international debates over the governance of genetic research in China, a country that has already seen major controversies over human gene editing in the past. Each newly documented incident strengthens, in international scientific opinion, the demand for stronger external oversight of any clinical trial involving modification of the human genome, regardless of the country where it takes place.

This demand is not meant to single out Chinese research as a whole: it applies equally to trials conducted elsewhere in the world whenever internal control mechanisms fail to protect patients ahead of the institutional or financial interests of the research teams involved.

What the parents now expect

The sources consulted do not spell out explicitly the formal demands made by Mei's parents beyond handing documents to Science. It is nonetheless reasonable to consider, in light of their actions, that they are seeking public acknowledgment of the exact circumstances of their daughter's death, rather than a vague institutional statement signed by a distant leadership.

A family that turns to Science rather than a local court has not only lost a child; it has also lost faith in the institutions meant to protect her. It is this loss of trust, as much as the death itself, that the university inquiry will now need to try to repair, if it genuinely intends to.

The weight of institutional silence against scientific transparency

A culture of publication that failed

The scientific publishing system rests on the assumption that authors disclose all relevant data, including failures and serious incidents. Qiu's paper in Nature illustrates a direct failure of that founding assumption: a partial success was presented without the negative data that accompanied it, in a journal that depends precisely on the good faith of its authors to function. Trust between researchers and journals is not a bonus; it is the foundation.

Nature's review committees, like those of most major journals, generally do not have the means to independently verify every piece of data submitted by authors. This case illustrates the structural limits of that system, which relies heavily on voluntary disclosure by researchers rather than systematic verification of every underlying clinical trial. A system built on good faith does not survive a researcher who alone decides what to withhold.

What this means for future gene therapy trials

Beyond Mei's case, this affair could have consequences for how ethics committees around the world now evaluate applications for experimental gene therapy trials, particularly when preclinical data on primates already raise documented concerns before any move to humans. A precedent this serious never stays confined to a single institution.

It is likely that voices will rise within the international scientific community to demand stronger disclosure obligations imposed on researchers before any publication concerning clinical trials that resulted in a death, regardless of the outcome of the inquiry opened at Shanghai Jiao Tong. A disclosure obligation that depends on a researcher's goodwill is not an obligation at all.

The international dimension of the scandal

Coverage that crosses far beyond China's borders

The initial revelation by Science and Retraction Watch was picked up as early as July 23 by media outlets thousands of kilometers from Shanghai: Chosun Biz in South Korea, The Epoch Times in the United States, Bloomberg for an international financial audience, and Breitbart for its American conservative readership. This rapid spread shows the scandal was immediately perceived as a credibility test for global genetic research as a whole, not just for one university team in Shanghai. A scandal relayed on three continents within days never stays a purely local matter.

This international coverage also places additional pressure on the university and on Nature itself: a case followed by newsrooms on several continents is harder to close with a simple internal statement than a purely local incident confined to the Chinese press would be. International scrutiny changes the institutional rules of the game.

What this says about the role of specialized science journalism

The joint role played by Science, a peer-reviewed journal, and by Retraction Watch, an independent watchdog platform, illustrates a complementarity that has become essential in detecting serious scientific misconduct. One holds the editorial credibility to give the accusation weight; the other holds the specific expertise to document retractions and fraud documented around the world. Without outside oversight, a hospital investigates itself, judges itself, and almost always forgives itself.

It took two specialized press organizations, and a grieving family, to do what the institution itself never did on its own. This dependence on outside actors remains, in itself, a troubling finding for research governance.

What comparable precedents in the genetic field reveal

A sector already marked by major controversies

Human gene editing has already seen, in the past, resounding controversies involving researchers who intervened on embryos or patients without fully disclosing the risks involved. This new case fits the same pattern: a technique presented as promising, a researcher eager to publish, and unfavorable data set aside at the moment of public communication of the results. Four sick monkeys should have stopped this trial before it reached a child.

What distinguishes this case is the precise combination of three elements rarely found together in a single scandal: a documented human death, an omission in a top-tier journal like Nature, and a financial payment whose nature remains to be clarified. Each of these three elements alone would have been enough to trigger a controversy; together, they form a case of rare gravity in this field of research.

Why comparisons with other countries let no one off the hook

It would be tempting, for some commentators, to reduce this affair to a problem specific to China's research system. That reading ignores that comparable failures — omission of negative data, incomplete publication, excessive disclosure delays — have also been documented in clinical trials conducted in Europe and North America over recent decades. The problem is not geographic; it is structural, wherever publication pressure exceeds the obligation of transparency. Geography excuses no one; only independent verification protects a patient.

This nuance in no way minimizes the gravity of Mei's case: it simply recalls that the solution does not lie in selective distrust toward a single country, but in a global strengthening of independent verification mechanisms before any scientific publication concerning trials involving human beings, wherever they take place.

What the financial press takes away from this affair

A signal sent to biotech sector investors

The coverage this affair received from Bloomberg, a leading financial outlet, indicates the scandal reaches beyond academia and also touches investor perception of the gene therapy sector. A company or laboratory associated, closely or distantly, with incomplete disclosure practices now faces a reputational risk that markets are known to punish quickly. Money follows trust, and trust has just delivered its verdict.

This financial dimension should not, however, eclipse the central human stake of this case: the death of a six-year-old child. A precedent this serious never stays confined to a single institution, nor to a single country.

What China itself let filter through

Global Times, a Chinese state-run outlet, itself reported the opening of the university inquiry, which indicates Chinese authorities did not seek to block all domestic coverage of the affair, even though the tone and angle of that outlet necessarily differ from those of the Western press. This partial but real coverage deserves to be noted as a fact, without drawing conclusions about the true extent of the transparency the university has promised.

It remains to be seen whether this partial transparency will translate, in the coming weeks, into the publication of detailed and verifiable findings, or whether it will be limited to general institutional communication with no precise answers to the financial and ethical questions this inquiry has raised.

What this affair establishes, with the caution that facts still partly under inquiry demand, comes down to a few dry lines: a child died in March 2025 from an experimental therapy, the incident was hidden for sixteen months, a major scientific publication omitted this death and the side effects observed in animals, and a payment of 860,000 dollars contradicts the claimed non-commercial nature of the trial. Each of these elements rests on documents or precise institutional findings, not on an unverified assumption.

What the inquiry opened on July 26 cannot yet settle is whether this concealment resulted from a coordinated decision or an accumulation of individual silences. The difference is not merely legal: it will determine whether this scandal remains an isolated case or reveals a structural flaw in how cutting-edge genetic research accounts for its failures. A therapy that repairs a gene never, on its own, repairs the trust it broke by hiding its own failure.

Signed Maxime Marquette, columnist

Columnist's Transparency box

Editorial positioning

This investigation is written from an acknowledged angle favoring scientific transparency and patient protection, which guides the choice of facts emphasized, without implying a fixed categorization of any real person named in this text. Professor Zilong Qiu is presented through documented acts — a publication, an omission, a reported statement — not through a moral judgment presented as an established fact. The ongoing university inquiry has not yet issued definitive conclusions on the precise responsibilities of each actor involved.

Methodology and sources

This text relies on the journalistic revelations of Science and Retraction Watch from July 23, 2026, relayed by Chosun Biz, as primary sources for the timeline of the death and its disclosure. These elements were put in context using the South China Morning Post, The Epoch Times, Bloomberg and Global Times for details on the 2025 fine, Qiu's statement, and the 860,000-dollar payment. Every figure has been explicitly attributed to its source; where information came from only one party, that limitation is flagged in the text rather than concealed.

Nature of the analysis

This text distinguishes three categories of information: corroborated facts backed by concrete documents (mortality report, Nature publication, proof of payment); elements still under inquiry, such as precise institutional responsibility for the concealment; and the columnist's analysis, clearly identified by tone, which addresses the scandal's significance for public trust in genetic research, never the legal guilt of any person named in this case.

Sources

Primary sources

Chosun Biz — Gene-editing scandal in China, girl's death revealed after more than a year — July 28, 2026

South China Morning Post — Chinese scientist faces probe after girl, 6, dies following experimental gene therapy — July 26, 2026

Global Times — Report on the university inquiry opened at Shanghai Jiao Tong — July 28, 2026

Secondary sources

The Epoch Times — University reviewing gene-editing research after family discloses daughter's death — July 28, 2026

Bloomberg — Patient death in China gene-editing trial draws fire, Science says — July 24, 2026

Breitbart — Six-year-old girl subjected to brain gene-editing therapy dies after being injected with viruses — July 27, 2026